Results 11 to 20 of about 134,715 (210)

Clopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?

European Journal of Medical Research, 2010
Background Dual therapy with aspirin and clopidogrel increases the risk of gastrointestinal bleeding. Therefore, co-therapy with a proton pump inhibitor (PPI) is recommended by most guidelines.
Kenngott S, Olze R, Kollmer M, Bottheim H, Laner A, Holinski-Feder E, Gross M   +6 more
doaj   +1 more source

Clopidogrel resistance: The way forward

Indian Heart Journal, 2014
Clopidogrel, a second generation thienopyridine has been the mainstay of ACS (Acute Coronary Syndrome) treatment for more than a decade. Clopidogrel Resistance has been associated with increased mortality in ACS patients with an increase in number of ...
Shuvanan Ray
doaj   +1 more source

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION

Рациональная фармакотерапия в кардиологии, 2015
Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj   +3 more sources

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI

Indian Heart Journal, 2015
Background: A thorough understanding of the patient's genotype and their functional response to a medication is necessary for improving event free survival.
P.C. Rath, Sundar Chidambaram, Pallavi Rath, Byomakesh Dikshit, Sudhir Naik, Prashant K. Sahoo, Brajraj Das, Mohanshankar Mahalingam, Lakshmipathi Khandrika, Jugnu Jain   +9 more
doaj   +1 more source

A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy

Scientific Reports, 2021
Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor.
Yu Ueda, Ronald H. L. Li, Nghi Nguyen, Eric S. Ontiveros, Samantha L. Kovacs, Maureen S. Oldach, Karen M. Vernau, Michael H. Court, Joshua A. Stern   +8 more
doaj   +1 more source

Thromboelastography evaluation of low response to clopidogrel in patients with acute coronary syndrome

International Journal of Gerontology, 2018
Summary: Background: This study aims to measure platelet aggregation with thromboelastography (TEG) and observe low response to clopidogrel in patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy.
Lijia Zhao, Xiaowei Xu, Fenghe Du, Buxing Chen   +3 more
doaj   +1 more source

Outcome of stroke patients on clopidogrel plus proton-pump inhibitors: a single-center cohort study

Annals of Saudi Medicine, 2019
BACKGROUND: Recent studies suggest a higher risk of adverse cardiovascular outcome and mortality in patients co-prescribed clopidogrel with proton pump inhibitors (PPI). OBJECTIVE: Investigate the impact of concomitant prescription of clopidogrel and PPI
Rahaf A. Alghamdi, Sina Marzoughi, Muath S. Alghamdi, Aisha Alghamdi, Mohammed Almekhlafi   +4 more
doaj   +1 more source

Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients

Swiss Medical Weekly, 2012
BACKGROUND: Patients who have acute coronary syndromes with or without ST-segment elevation have high rates of major vascular events. We evaluated the efficacy of early clopidogrel administration (300 mg) (
Jean Christophe Stauffer, Jean Jacques Goy, Nicole Duvoisin, Dragana Radovanovic, Hans Rickli, Paul Erne   +5 more
doaj   +1 more source

Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate

Brazilian Journal of Cardiovascular Surgery
Introduction: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. Objective: Identify predictors of clopidogrel following CABG.
Paulo Roberto L. Prates, Judson B. Williams, Rajendra H. Mehta, Susanna R. Stevens, Laine Thomas, Peter K. Smith, L. Kristin Newby, Renato A. K. Kalil, John H. Alexander, Renato D. Lopes   +9 more
doaj   +1 more source

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source